SPECIAL REPORT: Blockbusters Then and Now--Trends for Billion-Dollar Drugs

Table of Contents

• Executive Summary
  • Strategic Considerations
  • Stakeholder Implications
• Introduction
• Retrospective: Pharmaceutical Blockbuster Trends Since 1996
  • Methodology
  • Trends in the Number of Blockbusters, 1996-2006
  • Trends in the Type of Drugs Achieving Blockbuster Status, 1996-2006
  • Trends in Companies Producing Blockbusters, 1996-2006
  • Trends in the Therapeutic Areas of Blockbusters, 1996-2006
• Examples of Recently Failed, Highly Anticipated Blockbusters
  • Sanofi -Aventis' s Acomplia (Rimonabant)
  • Pfi zer' s Torcetrapib
  • Neurochem' s Alzhemed (Tramiprosate)
  • Upcoming Patent Effects on Current Blockbusters
• Review of Emerging Blockbusters
  • Emerging Blockbusters to Treat Metabolic Disease
    • Novartis' s Galvus (Vildagliptin)
    • Merck' s Cordaptive (ER niacin and laropiprant)
  • Emerging Blockbusters for Cardiovascular Disease
    • Novartis' s Exforge (Amlodipine & Valsartan)
  • Emerging Blockbusters for Oncology
    • GlaxoSmithKline' s Tykerb (Lapatinib)
  • Emerging Blockbusters for Infectious Diseases
    • Merck' s Isentress (Raltegravir)
  • Emerging Blockbusters for Psychiatric Disorders
    • Wyeth' s Pristiq (Desvenlafaxine)
• Conclusion

Tables

• 1. Top Blockbuster Companies, 1996-2000
• 2. Top Blockbuster Companies, 2001-2006
• 3. Total Number of Blockbusters by Company, 1996-2006
• 4. Patent Expiries in Major Markets of the 10 Top-Selling 2006 Blockbusters
• 5. Development Status and Anticipated Launch Year of Emerging Blockbusters

Figures

• 1. Growth in Number of Blockbusters Worldwide, 1996-2006
• 2. Select Companies' Late-Stage Pipelines vs. Anticipated 2012 Patent Expiries
• 3. Number of Conventional-Technology Blockbusters vs. Biotechnology Blockbusters, 1996-2006
• 4. Number of Blockbusters by Therapeutic Area, 1996-2000
• 5. Number of Blockbusters by Therapeutic Area, 2001-2006
• 6. Prevalent Cases of Select Metabolic Diseases in the Major Markets, 2006
• 7. Major-Market Value of Select Metabolic Disease Segments, 2006
• 8. Major-Market Value of Breast and Renal Cancer Therapies, 2005
• 9. Prevalent Cases of Breast and Renal Cancer in the Major Markets, 2006
• 10. Major-Market Value of Bipolar and Major Depression Therapies, 2005
• 11. Prevalent Cases of Bipolar and Major Depression in the Major Markets, 2006
• A. Projected Growth in Biologics Sales, 2001-2010

Expert Commentaries

• Exubera: What Went Wrong?
• Biologics Blockbusters-Decreased Vulnerability to Biosimilars and "Me Too" Drugs Portends Better Prospects for Blockbuster Sales Sustainability
• Big Pharma' s Interest in Biotech: Will the Trend Continue or Do Troubles Lie Ahead?